Back to thiazide-diuretics for hypertension: Reflections after a decade of irrational prescribing

BMC Family Practice

Volumn 4, Issue , 2003, Pages 1-4

  Fretheim, Atle ^a  

^a Norwegian Direct Hlth/Social Aff ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG INDUSTRY; HEALTH CARE MANAGEMENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PHYSICIAN; PRESCRIPTION; REVIEW; SIDE EFFECT; STROKE;

EID: 3042668414     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-4-19     Document Type: Review

References (27)

1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-838.
2. Kaplan NM: Antihypertensive drugs: how different classes can impact patients' coronary heart disease risk profile and quality of life. Am J Med 1987, 82:9-14.
3. Poulter N, Thom S, Sever P: First line treatment in hypertension. BMJ 1991, 302:116.
4. Swales JD: First line treatment in hypertension. BMJ 1990, 301:1172-1173.
5. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
7. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975.
8. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
9. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
10. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
11. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ: A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592.
12. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003, 289:2534-2544.
13. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
14. Fretheim A, Aaserud M, Oxman AD: The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Serv Res 2003, 3:18.
15. Chalmers J: All hats off to ALLHAT: a massive study with clear messages. J Hypertens 2003, 21:225-228.
16. Kaplan NM: The meaning of ALLHAT. J Hypertens 2003, 21:233-234.
17. Fagard RH: The ALLHAT trial: strengths and limitations. J Hypertens 2003, 21:229-232.
18. Goodman B: Do drug company promotions influence physician behavior? West J Med 2001, 174:232-233.
19. Prosser H, Almond S, Walley T: Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract 2003, 20:61-68.
20. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA: Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999, 282:771-778.
21. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999, 282:786-790.
22. Stelfox HT, Chua G, O'Rourke K, Detsky AS: Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998, 338:101-106.
23. Fretheim A, Williams J, Oxman A, Herrin J: The relation between methods and recommendations in clinical practice guidelines for hypertension and hyperlipidemia. J Fam Pract 2002, 51:963-968.
24. Lenzer J: Marketing: Spin doctors soft pedal data on antihypertensives. BMJ 2003, 326:170.
25. Oxman AD, Thomson MA, Davis DA, Haynes RB: No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995, 153:1423-1431.
26. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli R, Harvey E, Oxman A, O'Brien MA: Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001, 39:112-45.
27. Fretheim A, Oxman AD, Treweek S, Bjorndal A: Rational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice [ISRCTN48751230]. BMC Health Serv Res 2003, 3:5.